Cytotoxicity of Paclitaxel Incorporated in PLGA Nanoparticles on Hypoxic Human Tumor Cells

Jin, Cheng; Bai, Ling; Wu, Hong; Song, Wenjie; Guo, Guozhen; Dou, Kefeng

doi:10.1007/s11095-009-9889-z

Cited by 89 publications

(51 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jin and co-workers [455] demonstrated an enhanced in vitro cytotoxicity of the paclitaxel in breast carcinoma (MCF-7) and cervix carcinoma (HeLa) cell lines, compared to the free drug, observing cellular uptake by fluorescence microscopy. In addition, using mice they observed the biodistribution of the paclitaxel-loaded particles to the liver and the spleen.…”

Section: Paclitaxel Encapsulationmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,460

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

Section: Paclitaxel Encapsulationmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,460

754

View full text Add to dashboard Cite

show abstract

“…However, NPs can get trapped in the lung immediately after IV injection being a result of lung capillary filtration effects. 70 NPs can become physically entrapped in the lung or get recognized by the lung phagocytic macrophages. PLGA NPs appear to contribute to higher docetaxel concentrations in lung compared to PLGA-PEG NPs (during the first few time points) (P,0.05).…”

Section: Docetaxel In Mouse Heartmentioning

confidence: 99%

Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile

Rafiei

Haddadi

2017

IJN

230

140

View full text Add to dashboard Cite

Docetaxel is a highly potent anticancer agent being used in a wide spectrum of cancer types. There are important matters of concern regarding the drug’s pharmacokinetics related to the conventional formulation. Poly(lactide- co -glycolide) (PLGA) is a biocompatible/biodegradable polymer with variable physicochemical characteristics, and its application in human has been approved by the United States Food and Drug Administration. PLGA gives polymeric nanoparticles with unique drug delivery characteristics. The application of PLGA nanoparticles (NPs) as intravenous (IV) sustained-release delivery vehicles for docetaxel can favorably modify pharmacokinetics, biofate, and pharmacotherapy of the drug in cancer patients. Surface modification of PLGA NPs with poly(ethylene glycol) (PEG) can further enhance NPs’ long-circulating properties. Herein, an optimized fabrication approach has been used for the preparation of PLGA and PLGA–PEG NPs loaded with docetaxel for IV application. Both types of NP formulations demonstrated in vitro characteristics that were considered suitable for IV administration (with long-circulating sustained-release purposes). NP formulations were IV administered to an animal model, and docetaxel’s pharmacokinetic and biodistribution profiles were determined and compared between study groups. PLGA and PEGylated PLGA NPs were able to modify the pharmacokinetics and biodistribution of docetaxel. Accordingly, the mode of changes made to pharmacokinetics and biodistribution of docetaxel is attributed to the size and surface properties of NPs. NPs contributed to increased blood residence time of docetaxel fulfilling their role as long-circulating sustained-release drug delivery systems. Surface modification of NPs contributed to more pronounced docetaxel blood concentration, which confirms the role of PEG in conferring long-circulation properties to NPs.

show abstract

“…Many studies on drug loading, release and permeation have been performed through chitosan films (1)(2)(3)(4). Poly(D,L-lactic-co-glycolic acid) (PLGA) is another biodegradable polymer that has been widely used as nano/microparticles for encapsulation of drugs such as Paclitaxel (5)(6)(7)(8)(9). Paclitaxel is one of the most important chemotherapeutic drugs whose fast clearance from the body has hampered its widespread application.…”

Section: Introductionmentioning

confidence: 99%

“…Paclitaxel is one of the most important chemotherapeutic drugs whose fast clearance from the body has hampered its widespread application. The incorporation of paclitaxel in PLGA NPs has been reported as a strategy for increasing its resident time in the tumor and reducing systemic side effects (5)(6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Chitosan Film Containing Poly(D,L-Lactic-Co-Glycolic Acid) Nanoparticles: A Platform for Localized Dual-Drug Release

et al. 2010

View full text Add to dashboard Cite

show abstract

Cytotoxicity of Paclitaxel Incorporated in PLGA Nanoparticles on Hypoxic Human Tumor Cells

Abstract: Paclitaxel-loaded PLGA nanoparticles may be considered a promising drug delivery system to eradicate hypoxic tumor cells.

Cited by 89 publications

References 43 publications

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile

Chitosan Film Containing Poly(D,L-Lactic-Co-Glycolic Acid) Nanoparticles: A Platform for Localized Dual-Drug Release

Contact Info

Product

Resources

About